SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (966)7/6/1998 10:30:00 PM
From: billy d  Read Replies (1) | Respond to of 10280
 
Mazen,

Claritin D is just another form of Claritin with a decongestant. As far as I know, SEPR receives no royalties from it. (unless they improve that one too)

Also, so much for underperformance. Just when things look their worst, SEPR puts in a strong move up. So much for chart reading. This move would have fooled the best tea leave reader.

A couple more days of good volume and I'll bet we see 55 by the end of July.



To: M. Ramle who wrote (966)7/7/1998 1:11:00 AM
From: rkrw  Respond to of 10280
 
Ramle,
Claritin D has been approved and is on the market. It is not legal to advertise unapproved drugs in the US.

Sepracor received an upfront payment in the DCL deal. The deal encompasses any formulation containing DCL, such as DCL-D, rapidly dissolving, gelcap, liquid, whatever. Royalties will start when sales begin. This won't be for a couple of years, assuming successful completion of clinicals and FDA approval.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News